

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 March 2004 (25.03.2004)

PCT

(10) International Publication Number  
**WO 2004/024773 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 16/30**,  
A61K 39/395, A61P 35/00

(74) Agent: **BLAKE DAWSON WALDRON PATENT SER-  
VICES**; 39th Floor, 101 Collins Street, Melbourne, Victo-  
ria 3000 (AU).

(21) International Application Number:  
PCT/AU2003/001209

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,  
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:  
16 September 2003 (16.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
2002951409 16 September 2002 (16.09.2002) AU

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **THE  
QUEEN ELIZABETH HOSPITAL** [AU/AU]; 28  
Woodville Road, Woodville, South Australia 5011 (AU).

**Published:**

— *with international search report*

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **STEPHENSON,  
Sally-Anne** [AU/AU]; 4/4 West Street, Hectorville, South  
Australia 5073 (AU).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **METHODS FOR REGULATING CANCER**

(57) Abstract: The present invention provides methods for inhibiting cancerous growth of a cell using an antibody or an antigen-binding portion thereof which binds to an epitope of EphB4 polypeptide. Purified antibodies of EphB4 are also provided. The invention also provides methods for preventing or treating cancer. The invention also relates to methods of identifying agents that can inhibit cancerous growth of a cell.

**BEST AVAILABLE COPY**

## **Methods For Regulating Cancer**

### **Field of the invention:**

The present invention relates to methods for regulating cancer. In particular, the invention relates to methods for inhibiting cancerous growth of a cell. The invention  
5 also provides methods for preventing or treating cancer. The invention also relates to methods of identifying agents that can inhibit cancerous growth of a cell.

### **Background of the invention:**

Cancer describes a range of diseases, which result from dysregulated growth of cells of the body. Malignant cancers may develop from this dysregulated growth and  
10 subsequently spread around the body *via* the bloodstream or the lymphatic system, a process known as metastasis. Malignant tumours of epithelial tissues are the most common form of cancer and are responsible for the majority of cancer-related deaths in western industrialised countries. According to the Australian Institute of Health and Welfare (AIHW), on average one in three men and one in four women will develop  
15 cancer before the age of 75 years (1). In men the most common cancers are prostate, bowel and lung and in women, breast, bowel and melanoma. Identification of genes expressed specifically in tumour tissues and not in normal tissues, and analysis of their functions are useful for identifying new targets for cancer therapy.

Several genes have been implicated in various cancers. For instance, oncogenes  
20 are known to code for receptors for cellular growth factor such as epidermal growth factor. The *ras* gene is an oncogene that is believed to be responsible for up to 90% of all human pancreatic cancer, 50% of human colon cancers, 40% of lung cancers, and 30% of leukemias. Mutated oncogenes can become cancer-causing genes. Such mutated oncogenes code for proteins such as protein kinases and protein phosphorylating  
25 enzymes that trigger uncontrolled cell growth. *EphB4* is a recently identified member of the largest known family of receptor protein tyrosine kinases. Eph receptor family members have been identified to be involved in many cellular processes including neural development, angiogenesis and vascular network assembly (2-5). As a result of interactions with their ligands, the ephrins, they mediate contact-dependent cell

interactions, which regulate cell functions such as contact inhibition, cytoskeletal organisation and cell migration (6, 7).

Although a number of anti-cancer agents including growth inhibitory molecules such as cytotoxic compounds have been developed in an attempt to treat cancer, there still remains a need for providing effective methods for regulating cancer.

### **Summary of the invention:**

The present invention is based on the surprising finding that an antibody that can bind to a particular region of the EphB4 protein can advantageously inhibit cancerous growth in a cancer cell by causing cell death of the cancer cell.

- Therefore, in a first aspect the present invention provides a method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto.
- Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

- In a second aspect the present invention also provides a method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding

portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%,  
5 preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

In a third aspect the present invention provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein  
10 the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a  
15 sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at  
20 least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

In another aspect of the invention there is provided a method of identifying an agent which inhibits cancerous growth of a cell, the method comprises assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical  
25 thereto. Preferably, the method comprises assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the method comprises assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%,  
30 preferably at least 90% identical thereto. Most preferably, the method comprises assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at

least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The present invention also provides an agent identified by the method described above.

5 In a further aspect of the invention there is provided a purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1), preferably at least 90% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1). Preferably, the purified EphB4 antibody binds to a polypeptide having a sequence at least 85% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1),  
10 preferably at least 90% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1). The purified EphB4 antibody preferably binds to a polypeptide having a sequence at least 85% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1), preferably at least 90% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1). Most preferably, the present invention provides a purified EphB4 antibody which binds to an epitope located in  
15 residues 200 to 400 of EphB4 (SEQ ID NO: 1). The purified EphB4 antibody according to the present invention preferably binds to a polypeptide having a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1). Preferably, the purified EphB4 antibody is a monoclonal antibody.

## 20 **Brief description of the figures:**

Figure 1 shows immunohistochemical localisation of *EphB4* expression in three different colon cancers and matched normal mucosa using the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). The dark stain from the  
25 biotinylated secondary antibody indicates the EphB4 protein. Nuclei are stained with Harris haematoxylin. High power (100X) magnification images of three different adenocarcinomas (well differentiated, moderately well differentiated and poorly differentiated) and their matched normal mucosa are shown. Strong staining of the tumour tissue and very weak, diffuse staining of normal tissue was evident for each  
30 sample set. There was no cross-reactivity with the secondary antibody alone (result not shown).

Figure 2 shows relative RT-PCR comparing expression of *EphB4* (1187 bp) and internal 18S rRNA (489 bp) in five tumour (T) / normal (N) pairs. LM-Liver metastasis and NL-normal liver from patients 5, C1 – colon cancer cell line LIM2405, C2 – colon cancer cell line SW480, RT-RT negative control, P – PCR negative control, M – pUC19/ *HpaII* marker.

Figure 3 shows a confluent monolayer of cells in 2 ml DMEM is treated with a 1/500 dilution of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) (0.4 ng/ $\mu$ l final concentration). Incubation of cells with the antibody causes a visual response between 24 and 48 h. The cells lift off the bottom of the culture vessel in a fragile sheet which breaks up easily on gentle agitation. The change in colour of the media is due to a 0.5 pH unit change attributed to the leakage of cellular contents from dead cells.

Figure 4 shows a graph showing effect of increased doses of an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) on growth of MCF-7 cells *in vitro* after 48 hours.

Figure 5 shows a trypan blue exclusion assay to determine dose dependency of an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). The number of viable cells ( $\times 100000$ ) (Y-axis) decreases after 48h exposure to three different dilutions of the EphB4 antibody (X-axis). There were no viable cells remaining after 72h with the addition of 1 $\mu$ g /ml and after 48h with the addition of 2  $\mu$ g /ml.

Figure 6 shows a Caspase-3 assay. The relative amount of caspase-3 activity per 100000 cells (Y-axis) increases after time for all dilutions of an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) (X-axis). Because there were no viable cells counted for 1/200 dilution (1  $\mu$ g/ml) after 72h and for the 1/100 (2  $\mu$ g/ml) dilution after 48h, caspase-3 activity was not measured.

Figure 7 shows a graph showing percentage viability of breast cancer cells after 65 h treatment with five different EphB4 antibodies: (1) a EphB4 polyclonal antibody

(Swiss) directed to amino acid residues 825 to 991 of the carboxy terminus of mouse EphB4 (gift from Dr Andrew Ziemiecki, University of Bern), (2) a polyclonal N-terminal EphB4 antibody (N-19 Santa Cruz Biotechnology) directed to the N-terminal first 19 amino acids of the EphB4 amino acid sequence which is likely to be amino acids residues 16 to 34 of the mature EphB4 (SEQ ID NO:1), (3) a polyclonal EphB4 C-terminal antibody (C-16 Santa Cruz Biotechnology) directed to the carboxy-terminal corresponding to tyrosine kinase domain consisting of amino acid residues 615 to 874 of EphB4 (SEQ ID NO:1), (4) a EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) and (5) EphB4 polyclonal antibody (H-200 (old) -Santa Cruz Biotechnology -Lot number B141 batch) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). Cells were treated with 1/100 dilution of stock antibody (200 µg/ml), then stained with trypan blue (stains dead cells). Ratios of unstained (viable) to stained (unviable) were calculated for four different aliquots of each treatment. Control – no antibody added. CLM – complement limited medium. FCS – 10% Fetal calf serum added to medium. Complement does not play a role in the cell death effect of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). This is demonstrated by the comparison of percentage viability after antibody addition to cells grown in medium with normal protein activity (FCS experiment) with cells grown in medium in which complement proteins were inactivated by heating to 55°C for 30 mins (CLM Experiment).

Figure 8 shows a western analysis of normal human tissues as indicated and a representative colon tumour (Tumour). (A) EphB4 protein was identified using a EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). Predicted wildtype protein is 120 kDa and is indicated by the arrow. (B) Coomassie blue stained duplicate gel. Sizes of molecular weight marker are as indicated.

Figure 9 shows a schematic diagram comparing the domains of the wild-type EphB4 receptor with the predicted structure of the slice variants EphB4v1 and EphB4v2. Deleted regions are indicated by \*.

**Figure 10** shows an expression of *EphB4* gene and *PBGD* (housekeeping control) in breast cancer cell lines MDA-MB-231 (231), MDA-MB-468 (468), Hs578t, MCF7 and T47D either treated with 1/100 dilution of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) for 65 h (Treated) or with no treatment (control). RT-ve is the reverse transcription reagents only only control. Marker 1 – Spp1/EcoR1 and Marker 2 – pUC19/Hpa11.

**Figure 11** shows a sequences of the six overlapping peptides [shown as SEQ ID NO: 2 (Peptide 1) to SEQ ID NO:7 (Peptide 6)] designed to span the first 125 amino acids of the target EphB4 sequence (shown in bold). The numbers refer to the position of the amino acids in the mature EphB4 protein (SEQ ID NO:1 shown in Figure 18).

**Figure 12** shows a trypan blue exclusion assay comparing viability in control cells (untreated), cells with the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) alone (Ab only) or treated with both antibody and peptide cocktail (Ab + all peptides). Tests were performed in duplicate.

**Figure 13** shows an assay comparing relative levels of caspase-3 activity in control cells (untreated), cells with the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) alone, (Ab only) or treated with both antibody and peptide cocktail (Ab + all peptides). Tests were performed in duplicate.

**Figure 14** shows results of trypan blue exclusion assay performed 48 h after treatment on confluent SW480 monolayers with a 1/500 dilution of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) with or without 5 µl of peptides as indicated. Peptides 1 and 2 appeared to rescue ~50% of cells from Ab-mediated cell death.

**Figure 15** shows an increase in the concentration of Peptide 1 (SEQ ID NO:2) or Peptide 2 (SEQ ID NO: 3) (to 10 µl) was able to fully rescue cells from the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the



extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) mediated cell death and was equal in effect to a combination of Peptides 1 and 2 (5 µl of each).

**Figure 16** shows a sequences of the two overlapping peptides [shown as SEQ ID NO:2 (Peptide 1) and SEQ ID NO:3 (Peptide 2)] that were able to block the function of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) on cells in culture and sequences of three peptides [shown as SEQ ID NO:8 (Peptide 7) to SEQ ID NO:10 (Peptide 9)] designed about the core sequence GSCVV for further narrowing of the reactive sequence. The numbers refer to the position of the amino acids in the mature EphB4 protein (sequence shown in bold font).

**Figure 17** shows Peptide 7 (SEQ ID NO: 8) was able to fully rescue cells from Ab-mediated cell death and was equal in effect to Peptide 2 (SEQ ID NO: 3). One microlitre of the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) (0.2µg/ml) and 10 µl of a 10 mg/ml stock of peptide were pre-incubated together on ice for 2 h before addition to a confluent monolayer of cells in a 24-well microtitre plate with 500 µl of DMEM.

**Figure 18** shows the amino acid sequence of SEQ ID NO:1. SEQ ID NO:1 is the amino acid sequence of mature *Homo sapiens* Ephrin type-B receptor 4 (EphB4).

**Figure 19.** shows a model of the EphB4 receptor with domain regions to which the different polyclonal antibodies (N-19, H-200 and C-16) have been targeted indicated by black brackets. The globular domain (ephrin receptor ligand binding domain) corresponds to residues 29 to 197 of EphB4 (SEQ ID NO:1). The cysteine-rich region (Giardia variant-specific surface protein) corresponds to residues 255 to 313 of EphB4 (SEQ ID NO:1). The fibronectin type III domain 1 corresponds to residues 324 to 414 of EphB4 (SEQ ID NO:1). The fibronectin type III domain corresponds to residues 437 to 517 of EphB4 (SEQ ID NO:1). The transmembrane domain corresponds to residues 540 to 560 of EphB4 (SEQ ID NO:1). The tyrosine kinase domain corresponds to residues 615 to 874 of EphB4 (SEQ ID NO:1). The SAM (sterile alpha motif) domain corresponds to residues 904 to 971 of EphB4 (SEQ ID NO:1). The PDZ domain corresponds to residues 985 to 987 of EphB4 (SEQ ID NO:1).

The placements of these domains relative to the EphB4 amino acid sequence is based on information taken from the most recent report from NCBI Accession number NP\_004435. The N-19 Antibody maps to the N-terminal first 19 amino acids of the sequence which is likely to be amino acids residues 16 to 34 of the mature EphB4 (SEQ ID NO:1). The C-16 antibody is directed to the tyrosine kinase domain. The H-200 antibody is specifically directed to residues 201 to 400 of EphB4 (SEQ ID NO:1) in the extracellular domain spanning the cysteine rich region and the fibronectin domain.

Figure 20 shows a sequence of a Peptide 11 (SEQ ID NO: 12) designed to include the proposed epitope sequence and a Peptide 10 (SEQ ID NO:11) in which the amino acid Aspartate (D) which carries a charge in this wild-type sequence is substituted with an uncharged amino acid with a similar side chain structure Asparagine (N). The numbers and the sequence in bold font refer to the position of the amino acids in the mature EphB4 protein.

#### **Detailed description of the invention:**

In a first aspect the present invention provides a method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The antibody or an antigen-binding portion thereof preferably specifically binds to a polypeptide having a sequence consisting of residues 200 to 400 of EphB4 (SEQ ID NO:1). Preferably, the antibody or antigen-binding portion specifically binds to a polypeptide having a sequence consisting of residues 201 to 245 of EphB4 (SEQ ID NO:

1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion specifically binds to a polypeptide having a sequence consisting of residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof specifically binds to a polypeptide having a sequence consisting of residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1). Most preferably, the antibody or an antigen-binding portion thereof is a polyclonal or monoclonal antibody. The method preferably results in the death of the cell.

The antibody or antigen-binding portion thereof preferably specifically binds to a polypeptide having a sequence at least 85%, preferably at least 90% identical to sequence selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1). A polypeptide having a sequence at least 85%, preferably at least 90% identical to residues 200 to 400 of EphB4 (SEQ ID NO:1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) or residues 220 to 230 of EphB4 (SEQ ID NO: 1), preferably includes polypeptide variants having at least one substitution, deletion or addition of particular amino acids(s). Such polypeptide variants are also suitable for the present methods, particularly if they retain antigenic properties. For instance, the polypeptide variants can be designed to retain antigenic properties and to improve polypeptide production and/or solubility.

For example, antigenic prediction programs suggest that the charged amino acid Asp (D) may also be important to the epitope function as it is the only charged residue in the sequence. Peptide 11 consisting of amino acid residues 220 to 244 of EphB4 protein (SEQ ID NO.1) was designed as indicated in Figure 20. Peptide 10 with a substitution of Asn (N) at residue 226 of EphB4 protein (SEQ ID NO.1) was also designed as indicated in Figure 20). The amino acid sequence of Peptide 10 and Peptide 11 is as follows:

Peptide 10    SEQ ID NO:11:        AGSCVVNAVPA PGSPSLYCRE DGQ

Peptide 11    SEQ ID NO:12:        AGSCVVDAVPA PGSPSLYCRE DGQ

The side chains of Asp and Asn are very similar – the hydroxyl group of Asp is an amine in Asn and changes it from being a negatively charged amino acid to a neutral one.

In a second aspect the present invention also provides a method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

In a third aspect the present invention provides a method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The cancer is preferably selected from the group consisting of breast cancer, prostate cancer, bowel cancer, bladder cancer, colon cancer, ovarian cancer, lung cancer, melanoma, lymphoma and leukemia. The method preferably results in the death of a cancer cell in the subject.

5 In another aspect of the invention there is provided a method of identifying an agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto.

10 In a preferred embodiment of the invention, the agent binds to an epitope contained within residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the agent binds to an epitope contained within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or antigen-  
15 binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the agent binds to an epitope contained within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at  
20 residue 226 of EphB4 (SEQ ID NO: 1).

The present invention also provides an agent identified by the method described above.

In the present specification the term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific  
25 antibodies (e.g., bispecific antibodies), and antibody fragments. The term "epitope" refers to an epitope region of a polypeptide that is recognized by an antibody or an antigen binding portion thereof.

Antibodies refer to immunoglobulin molecules comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide  
30 bonds. Each heavy chain is comprised of a heavy chain variable region (HCVR or VH) and a heavy chain constant region. The heavy chain constant region is comprised of

three domains, CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (LCVR or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR, CDR1, FR2, CDR2, FR3, CDR3, FR4.

The term "antigen-binding portion" of an antibody (or simply "antibody portion"), as used herein refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment (8) which consists of a VH domain, or a VL domain (9); and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv)(10), (11). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. Other forms of single chain antibodies, such as diabodies or triabodies are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (12, 13). Preferably, the antibody is EphB4 (H-200) rabbit polyclonal Ig G antibody, Santa Cruz Biotechnology, Santa Cruz, California.

More preferably, the antibody is a monoclonal antibody or fragment thereof and, particularly, is selected from monoclonal antibodies or fragments thereof which bind to an epitope within residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the monoclonal antibodies or fragments thereof bind to an epitope within residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the monoclonal antibodies or fragments thereof bind to an epitope within residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the monoclonal antibodies or fragments thereof bind to an epitope within residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

In a further aspect of the invention there is provided a purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1), preferably at least 90% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1). Preferably, the purified EphB4 antibody binds to a polypeptide having a sequence at least 85% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1), preferably at least 90% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1). The purified EphB4 antibody preferably binds to a polypeptide having a sequence at least 85% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1), preferably at least 90% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1). More preferably, the present invention provides a purified EphB4 antibody which binds to an epitope located in residues 200 to 400 of EphB4 (SEQ ID NO: 1). The purified EphB4 antibody according to the present invention preferably binds to a polypeptide having a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1). More preferably, the purified EphB4 antibody is a monoclonal antibody.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations that typically include different

antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method, isolated from phage antibody libraries, or may be made by recombinant DNA methods. Such techniques include, but are not restricted to, the hybridoma technique (14), the trioma technique, the human B-cell hybridoma technique (15), and the EBV hybridoma technique to produce human monoclonal antibodies (16). In addition, humanised monoclonal antibodies can be generated according to methods described in US patent 6,090,382 of which the entire description and references cited therein are incorporated herein. The document provides suitable host cells for expressing recombinant human antibodies and methods of synthesising the recombinant human antibodies. Furthermore, suitable human antibodies may be produced using transgenic animals using for example techniques described in *Oncology* 29 (Supp 4) 47-50 (2002). The antibodies of the present invention may also be obtained from commercial sources.

Various procedures known in the art may also be used for the production of polyclonal antibodies which can bind to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. For production of the antibodies, various host animals can be immunized by injection with a EphB4 protein or a EphB4 polypeptide fragment bound to a suitable carrier. Suitable carriers can include, but are not limited to, BSA (bovine serum albumin), KLH (keyhole limpet hemocyanin), OVA (ovalbumin), THY (Thyroglobulin) and RSA (rabbit serum albumin). The host animal is preferably immunized with a EphB4 polypeptide comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the host animals can be immunized by injection with a EphB4 protein or a polypeptide comprising residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the host animals can be immunized by injection with a EphB4 protein or a polypeptide comprising residues 220 to 244 of



EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the host animals can be immunized by injection with a EphB4 protein or a polypeptide comprising residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence  
5 has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

Suitable host animals include, but are not limited to, rabbits, mice, rats, etc. Various adjuvants can be used to increase the immunological response, depending on the host species, and include, but are not limited to, Freud's (complete and incomplete),  
10 mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, and potentially useful human adjuvants such as *Bacillus Calmette-Guerin* (BCG) and *Corynebacterium parvum*. Antibodies and antibody fragments may be produced in large amounts by standard techniques (eg in either tissue culture or serum free using a fermenter) and  
15 purified using affinity columns such as protein A (eg for murine Mabs), Protein G (eg for rat Mabs) or MEP HYPERCEL (eg for IgM and IgG Mabs).

Suitable antibodies may include antibody fragments that include an antigen-binding portion that can bind to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90%  
20 identical thereto. The antigen-binding portion of an antibody preferably includes idiotypes of residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody fragments include an antigen-binding portion that can bind to a polypeptide having a sequence comprising residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at  
25 least 90% identical thereto. Preferably, the antibody fragments include an antigen-binding portion that can bind to a polypeptide having a sequence comprising residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody fragments include an antigen-binding portion that can bind to a polypeptide having a sequence comprising residues 220 to 230  
30 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

Such antibody fragments can be generated by techniques known in the art. For example, such fragments include, but are not limited to, the F (ab')<sub>2</sub> fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments that can be generated by reducing the disulfide bridges of the F (ab')<sub>2</sub> fragment, the Fab  
5 fragments that can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments. In a further technique, recombinant antibodies specific to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably, residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably, residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably, residues 220 to 230 of  
10 EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, can be engineered and ectopically expressed in a wide variety of cell types. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The antibodies used in the present methods can include "humanized" forms of  
15 non-human (eg., murine) antibodies that are immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal amino acid residues derived from a non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary  
20 determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human FR residues. Furthermore, a humanized antibody may comprise residues which are found neither in  
25 the recipient antibody nor in the imported CDR or framework sequences. These modifications can be made to further refine and optimize antibody performance.

The term "EphB4 protein" as used herein is taken to include full length EphB4 protein or a polypeptide fragment that comprises residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably,  
30 the EphB4 protein includes a polypeptide fragment that comprises residues 201 to 245 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the EphB4 protein includes a polypeptide fragment that comprises

residues 220 to 244 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the EphB4 protein includes a polypeptide fragment that comprises residues 220 to 230 of EphB4 (SEQ ID NO: 1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a  
5 substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

A EphB4 variant protein may be modified at the amino acid level and may include additions or deletions or replacements of amino acids which do not affect the functionality of the protein, such as conservative amino acid substitutions. An EphB4 protein may also include a truncated EphB4 protein. An EphB4 protein may be natural  
10 or recombinant. The EphB4 protein may be from any animal species, preferably the EphB4 protein is human.

An antibody or an antigen-binding portion thereof that is suitable for the methods of the present invention, preferably can inhibit cancerous growth of a cell by inhibiting the activity of an EphB4 protein. In the specification the term "cancerous  
15 growth" is taken to refer to abnormal and uncontrollable division and growth of a cell. Typically such a cell is identified as a cancer cell that may be able to invade and disrupt other tissues and has the potential to spread to other areas of the body. Cancerous growth of a cell can lead to the formation of a tumor that may be benign or malignant.

In the specification the term "cell(s)" is taken to include any cells. Preferably, the  
20 cells are derived from a mammalian species, such as, but not limited to, human, mice, bovine, sheep or domestic animals. It is preferred that the cells are selected from the group including, but not limited to, prostate cells, breast cells, colon cells, fibroblasts, epidermal cells, placental, liver, kidney, pancreas, heart, neural or muscle cells, or cancer or tumor cells. The cells may be normal cells, diseased cells, adult cells or embryonic  
25 cells. The cells may be single cells, cultured cells or part of a tissue. The cells may be genetically modified recombinant cells, such as a transgenic cell. Preferably, the cells express EphB4. The cells may be part of a whole animal. The cells may also be derived from a cell line. Preferably, the cells are from a cell line derived from, but not limited to, prostate, breast, colon or ovary cell line. The cell line is preferably selected from the  
30 group consisting of colon SW480, colon SW620, colon LIM1215, breast MCF7, breast T47-D, breast MDA-MB-231, breast MDA-MB-453, bladder J82, bladder T24, bladder RT119

and bladder 5637. More preferably, the cell line is selected from the group consisting of breast cancer cell line MCF-7 and colon cancer cell line SW480.

The antibody or an antigen-binding portion thereof of the present invention preferably can inhibit cancerous growth of one or more of cancer cells selected from the group consisting of breast cancer cells, prostate cancer cells, bowel cancer cells, bladder cancer cells, colon cancer cells, ovarian cancer cells, lung cancer cells, melanoma cells, lymphoma cells and leukemia cells.

The antibody or an antigen-binding portion thereof preferably specifically binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. In a preferred embodiment of the invention, at least one antibody or an antigen-binding portion thereof specifically binds to an epitope contained within residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto.

The term "specifically binds" in this specification, is to be understood to refer to binding characteristics of an antibody or an antigen-binding portion thereof which binds exclusively to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. The antibody or an antigen-binding portion thereof is preferably a polyclonal or monoclonal antibody that specifically binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody is an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1).

The present invention provides a method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

10        Preferably, at least one antibody or an antigen-binding portion thereof binds to a polypeptide having a sequence comprising residues 201 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or an antigen-binding portion thereof binds to a EphB4 protein having a sequence comprising residues 201 to 245 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the antibody or an antigen-binding portion thereof binds to a EphB4 protein having a sequence comprising residues 220 to 244 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. More preferably, the antibody or an antigen-binding portion thereof binds to a EphB4 protein having a sequence comprising residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

25        The phrase "inhibiting cancerous growth of a cell" as used herein is taken to mean that cancerous growth of the cell is substantially reduced or prevented. In the present invention a cell is contacted with at least one antibody or an antigen-binding portion thereof which binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, to result in the inhibition of cancerous growth of the cell as compared to an untreated cell. The method preferably results in the death of the cell. Preferably, the

sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The present invention also provides a method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof which binds to a polypeptide having a sequence comprising  
5 residues 200 to 400 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. In a preferred embodiment of the invention, at least one antibody or an antigen-binding portion thereof binds to an epitope contained within residues 201 to 245 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at  
10 least 90% identical thereto. Preferably, at least one antibody or an antigen-binding portion thereof binds to an epitope contained within residues 220 to 244 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. More preferably, at least one antibody or an antigen-binding portion thereof binds to an epitope contained within residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at  
15 least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

The phrase "inducing cell death of a cancer cell" is taken to mean that a cancer cell contacted with at least one antibody or an antigen-binding portion thereof which binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ  
20 ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, is caused to undergo cell death. Preferably, the antibody is an EphB4 polyclonal antibody (H-200 - Santa Cruz Biotechnology) specifically directed to the extracellular domain amino  
25 residues 201 to 400 of EphB4 (SEQ ID NO:1).

Cell death of a cancer cell may be assessed by a number of assays. For example, caspase-3 activation is considered to play a key role in the initiation of cellular events during cell death. Many different kits for the quantification of caspase-3 activity are available commercially. Mitochondrial membrane depolarization is often associated  
30 with the early stage of cell death. Changes in the membrane potential are presumed to be due to the opening of the mitochondrial permeability transition pores, which may play a central role in apoptosis. Depolarization can be detected by a number of different

assays including the use of Rhodamine 123, a green-fluorescent cationic dye that accumulates in active mitochondria, which have high membrane potentials allowing quick and easy detection of cellular disruption. Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme present in all cells. It is rapidly released into the cell culture supernatant when the plasma membrane is damaged. LDH activity can easily be measured in culture supernatant by a single point assay using a spectrophotometric plate reader using commercially available kits. Elevated LDH in the culture medium is an indication of cell necrosis (death).

The morphology of a cell can also be examined to assess cell death. For instance, apoptosis is programmed cell death which is characterised by a series of typical morphological events, such as shrinkage of the cell and fragmentation into membrane-bound apoptotic bodies (17). These can be seen using a light microscope. In addition, a cell can be examined for the expression of genes related to cell death. In addition, RT-PCR analysis comparing EphB4 antibody treated and untreated cells from four different breast cancer cell lines has shown that *EphB4* gene expression is down-regulated in treated cells.

A further aspect of the present invention is a method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof which binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1). The method preferably results in the death of a cancer cell in the subject.

The cancer is preferably selected from the group consisting of breast cancer, prostate cancer, bowel cancer, bladder cancer, colon cancer, ovarian cancer, lung cancer, melanoma, lymphoma and leukemia.

The subject treated by the methods of the invention may be selected from, but is not limited to, the group consisting of humans, sheep, cattle, horses, bovine, pigs, poultry, dogs and cats.

In the method an effective amount of at least one antibody or an antigen-binding portion thereof which binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, is administered to a subject. In a preferred embodiment of the invention, at least one antibody or an antigen-binding portion thereof binds to an epitope contained within residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. The antibody or an antigen-binding portion thereof preferably specifically binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the antibody or an antigen-binding portion thereof is a polyclonal or monoclonal antibody.

The term "effective amount" means a dosage sufficient to provide treatment or prevention for the cancer being treated or prevented. This will vary depending on the subject and the type of cancer being effected. The effective amounts of at least one antibody or an antigen-binding portion thereof used in the methods of the present invention may vary depending upon the manner of administration, the condition of the animal to be treated, and ultimately will be decided by the attending scientist, physician or veterinarian. The amount of antibody or an antigen-binding portion thereof used to treat or prevent a subject will also vary depending upon the nature and identity of the particular antibody or an antigen-binding portion thereof.

An antibody or an antigen-binding portion thereof is preferably administered to a subject by any suitable means known to those skilled in the art. Preferably, the antibody or an antigen-binding portion thereof can be contacted with a cell in numerous fashions, including, for example, intravenously.

Preferably, the antibody or an antigen-binding portion thereof of the present invention is combined with a suitable pharmaceutically-acceptable carrier or diluent to



form a pharmaceutical composition which may be suitable for administration to a human or animal subject. Suitable carriers or diluents include isotonic saline solutions, for example, phosphate-buffered saline. The pharmaceutical composition including at least one antibody or an antigen-binding portion thereof may be formulated for

5 parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral or transdermal administration. The antibody may be administered at a suitable dose dependent on the body weight of the subject. It is to be understood, however, that the routes of administration and dosages mentioned are intended to serve only as a guide since a person skilled in the art would be able to readily determine the optimum route of

10 administration and dosage for any particular subject and cancer.

The antibody or an antigen-binding portion thereof used in the methods of the present invention may be combined with suitable excipients, such as emulsifiers, surfactants, stabilisers, dyes, penetration enhancers, anti-oxidants, water, salt solutions, alcohols, polyethylene glycols, gelatine, lactose, magnesium stearate and silicic acid. The

15 antibody or an antigen-binding portion thereof is preferably formulated as a sterile aqueous solution. The antibody or an antigen-binding portion thereof can be combined with adjunct components that are compatible with the activity of the antibody. An antibody or an antigen-binding portion thereof used in the methods of the present invention may be preferably used to complement existing treatments for cancer. For

20 example, the method of the present invention may also be used in combination with traditional cancer treatments such as radiotherapy, chemotherapy (eg using anthracyclines, 5FU, topoisomerase inhibitors, Cisplatin and Carboplatin), or hormone therapy or therapies utilising hormone modifiers (eg Catamoxifen).

In another aspect of the invention there is provided a method of identifying an

25 agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical

30 thereto. In a preferred embodiment of the invention, the agent binds to an epitope contained within residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1),

more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Preferably, the agent binds to a EphB4 protein having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto.

In the present specification the term "agent" is taken to include any molecule, compound or protein that can bind (interact with) residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Suitable agents can preferably include an antibody or an antigen-binding portion thereof that binds to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Most preferably, the agent is an antibody or an antigen-binding portion thereof that is a polyclonal or monoclonal antibody. The method preferably comprises assessing the ability of the agent to induce cell death of a cancer cell. The agent is preferably a EphB4 ligand, such as an antibody or an antigen-binding portion thereof, that is preferably specific for EphB4 protein and may be developed or obtained commercially for testing in *in vitro* or *in vivo* systems for its ability to inhibit cancerous growth of a cell.

For instance, antibodies or antigen-binding portions thereof directed to specific epitopes of residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, can be tested for their ability to inhibit cancerous growth of a cell and preferably induce cell death. Dose response curves to assess the IC50 of the antibodies can be conducted to test efficacy of each antibody tested. In addition, antibody/receptor-ligand binding studies can be performed to assess the ability of the antibody to prevent ligand binding. Tyrosine phosphorylation of the EphB4 receptor following antibody binding can be assessed by

immunoprecipitation of the receptor with the respective antibody, followed by Western analysis with an anti-phosphotyrosine antibody to confirm that the EphB4 receptor is inactivated. The antibody with the best neutralising activity in terms of inhibiting tyrosine phosphorylation and cell growth *in vitro* and preventing ligand binding to the EphB4 receptor at the lowest 50% inhibitory concentration (IC<sub>50</sub>) can be selected for additional *in vivo* tests.

For instance, an *in vivo* model of metastasis and tumour growth using immune-deficient NOD-SCID (non-obese diabetic, combined immunodeficiency) mice can be used to test the ability of putative agents that can bind to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto, for their efficacy as an anti-cancer agent. Preferably, the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1). Moreover, a diverse array of tumor cell lines that are available, most of which can be grown as xenografts, and these include the human breast cancer cell line MCF-7 and colon cancer cell line HT29, can be used for *in vitro* testing. Xenograft tumours can be grown in the mouse model either after subcutaneous injection, where they will grow as a mass, or after injection into the tail vein allowing mimicry of the hematogenous spread of metastasis that results in secondary deposits in other organs. Once suitable engraftment periods and inoculation doses for each cell line have been established, the model can be used to test various agents that bind to a polypeptide having a sequence comprising residues 200 to 400 of EphB4 (SEQ ID NO:1), preferably residues 201 to 245 of EphB4 (SEQ ID NO:1), preferably residues 220 to 244 of EphB4 (SEQ ID NO:1), more preferably residues 220 to 230 of EphB4 (SEQ ID NO:1), or a sequence at least 85%, preferably at least 90% identical thereto. Cells may also be treated with sub-lethal doses of a chosen EphB4 antibody equating to the IC<sub>50</sub> and IC<sub>75</sub> to assess the engraftment of treated cells compared with non-treated cells. This will assess the effects of reduced functional expression of EphB4 on establishment and metastasis of tumour cell lines.

The *in vivo* models can also be used for pre-clinical assessment of potential new therapies for treatment of EphB4 positive tumours cell lines. The use of subcutaneous

injection will allow the examination of tumours that have been allowed to establish for different periods of time. This can be used to determine the ability of an agent, such as an antibody or an antigen-binding portion thereof, to ablate newly and well-established tumours compared to vehicle control. The use of tail vein injections can be used to determine whether treatment with an antibody or an antigen-binding portion thereof will reduce number of metastases formed as a result of hematogenous spread. The agents identified by the methods of the present invention may be used for treatment or prevention of cancer. The present invention also provides an agent identified by the method described above.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

The invention will hereinafter be described by way of the following non-limiting Figures and Examples.

#### **Example 1 – Immunohistochemical localisation of EphB4:**

An EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) was used to analyse the localisation of the EphB4 protein in tumour and normal tissue. Colon and breast tissue showed marked increase in the levels of this protein in the tumour epithelial cells when compared with the matched normal tissue (as shown in Figure 1). The demonstration of high expression of *EphB4* on the tumour epithelial cells in two of the most commonly occurring cancers suggests that EphB4 is critical to the progression of these tumours.

#### **Example 2 – RT-PCR expression of EphB4:**

Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to compare expression of *EphB4* (1187 bp) and internal 18S rRNA (489 bp) in five tumour (T) / normal (N) pairs (results shown in Figure 2). Analysis of 63 colon cancers from 60 patients indicated that *EphB4* is over-expressed in the tumour tissue of 80% of patients, implying broad application as a therapeutic target (Figure 2). The differential expression

between tumour cells and normal tissue suggests anti-EphB4 tumour therapy may have a preferential effect on colon (and other) tumours.

A comparison of the expression profile of *EphB4* with that of other receptor protein tyrosine kinases already being targeted in clinical trials (HER2, EGFR and VEGFR) suggests that *EphB4* is expressed to a lesser degree in normal tissues. Information from EST databases suggests that low level expression of *EphB4* may be present in kidney, ovary and placenta, and very low level expression in heart, lung, peripheral nerves and vascular tissue. Accordingly therapies that target EphB4 may be expected to produce less side effects than those that target other receptor tyrosine kinases.

### **Example 3 - EphB4- specific antibody studies:**

A direct tumoricidal effect of an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) *in vitro* was demonstrated. Incubation of a fully confluent monolayer of colon cancer cell lines SW480 and SW620 with a 1/500 dilution of EphB4 antibody H-200 (Santa Cruz Biotechnology - Lot numbers B141 and F182) caused the cells to lift off the bottom of the culture vessel and die (Figure 3). This was a common response seen when treating colon cancer cell lines including SW480, SW620, LIM1215, breast cancer cell lines MCF-7, T47-D, MDA-MB-453, MDA-MB-231 and Hs578t, bladder cancer cell lines J82, RT119, 5637 and T24.

Incubation of the breast cancer cell line MCF-7 and the colon cancer cell line SW480 with three different concentrations of antibody (2 µg/ml, 1 µg/ml and 0.2 µg/ml) resulted in cell death in a dose dependent manner (see Figure 4 and Figure 5). This effect was not seen following exposure of the endothelial cell line HUVEC-C to the EphB4 antibody. Analysis of the caspase-3 activity suggested that cell death was not *via* apoptosis (Figure 6). These results suggest that by cross-linking or binding to membrane receptors, antibodies may mimic or modulate receptor activity and that these antibodies-generated transmembrane signals might cause apoptosis or growth inhibition (18). Possible alternative mechanisms for the induction of cell death include ras-mediated non-apoptotic cell death or restoration of gap junction intercellular communication

(GJIC), a direct cell-cell communication pathway that is known to be prevented by Eph receptor signaling (19).

Polyclonal antibodies specific for EphB4 have been developed and are available commercially, for testing of these antibodies in *in vitro* and *in vivo* systems. Figure 7 shows results of the percentage viability of breast cancer cells after treatment with five EphB4 antibodies as detailed below:

(1) a EphB4 polyclonal antibody (Swiss) directed to amino acid residues 825 to 991 of the carboxy terminus of mouse EphB4;

(2) a polyclonal N-terminal EphB4 antibody (N-19 Santa Cruz Biotechnology) directed to the N-terminal first 19 amino acids of the EphB4 amino acid sequence which is likely to be amino acids residues 16 to 34 of the mature EphB4 (SEQ ID NO:1);

(3) a polyclonal EphB4 C-terminal antibody (C-16 Santa Cruz Biotechnology) directed to the carboxy-terminal corresponding to tyrosine kinase domain consisting of amino acid residues 615 to 874 of EphB4 (SEQ ID NO:1);

(4) a EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1);

(5) a EphB4 polyclonal antibody (H-200 (old) -Santa Cruz Biotechnology -Lot number B141 batch) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1).

Cell death effect was seen in treatment with the H-200 antibody specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). A comparison of cells grown in medium with or without active complement proteins shows that complement plays no role in the Ab-mediated cell death (see Figure 7).

The mechanism of cell death can be further by analysing changes to gene expression induced in cancer cells *in vitro* after incubation with sub-lethal doses of the H-200 EphB4 antibody using microarray techniques.

**Example 4 – Expression of EphB4 in human tissue:**

Information from EST databases and Northern analysis of normal human tissues (20) suggests that low level expression of *EphB4* may be present in kidney, ovary and placenta, and very low level expression in heart, lung, peripheral nerves and vascular tissue, and no expression in brain. In order to determine whether gene expression correlates with the level of protein actually translated a western analysis using these tissues was performed with an EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1). By comparison with a single colon tumour sample it was shown that the level of gene expression does not correspond to the amount of EphB4 protein produced in these tissues (Figure 8). The differential expression between tumour cells and normal tissue suggests that anti-EphB4 tumour therapy may have a preferential effect on colon tumours.

Several hybridising bands were obtained with Western blot analysis (data not shown). However, the identity of these protein bands that are specific to the tumour sample(s), and common to all tumour samples tested, remains to be determined but may correspond to splice variation. Two *EphB4* splice variants (named *EphB4v1* and *EphB4v2*) were identified. Determination of the *EphB4* gene structure has shown that *EphB4v1* results from the absence of the 53 amino acids encoded by the entire exon 16 (Figure 9). If *EphB4v1* is translated the resultant protein would lack a portion of both the kinase and SAM domains, two protein domains that are known to have roles in transmitting signals to intracellular targets. *EphB4v2* is caused by the in-frame deletion of the entire exon 6 which results in the absence of 111 amino acids. *EphB4v2* would encode a protein that lacks the first fibronectin type III repeat. The role of fibronectin type III repeats is not known and the effect of removing one of these repeats is unknown at this time.

**Example 5 – RT-PCR analysis of EphB4:**

Because of EphB4 possible role in angiogenesis, the expression of *EphB4* in endothelial cells using RT-PCR was performed. Low level of expression of EphB4 was observed. However, when these cells were grown in the presence of the EphB4

polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) there was no apparent change in cell growth or morphology, even at the highest concentration of antibody. The effect of the EphB4 antibody on the growth and morphology of NIH3T3  
5 cells was also tested. There was no morphological or growth response (data not shown). The nontumorigenic breast cell line MCF10A, established from mammary tissue from a 36-year old Caucasian patient with fibrocystic breast disease (21) was also tested and was observed to express EphB4 at low levels but did not respond to the anti-EphB4 antibody (data not shown). These results, when considered together with results gained  
10 from the western analysis of normal human tissues (Example 5), suggest that tissues that show a high level of *EphB4* expression will be negatively affected by an EphB4 antibody.

The results indicated that after treatment with the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology) specifically directed to the extracellular domain amino residues 201 to 400 of EphB4 (SEQ ID NO:1) the *EphB4* gene is down-regulated (Figure  
15 10). This agrees with the finding that most antibodies increase RTK down-regulation and internalisation of the receptor after blocking the ligand-receptor interaction and inhibiting ligand-induced RTK signaling. This is since certain antibodies can influence tumour growth by altering the intracellular signaling pattern inside the targeted tumour cell. The analysis of global changes in gene expression in Ab-treated cells compared to  
20 untreated cells may identify genes involved in EphB4-related signaling.



**Example 6 -EphB4 antibody- Epitope mapping:**

A EphB4 commercially available H-200 polyclonal Ab from Santa Cruz is raised  
 5 against a recombinant protein corresponding to amino acids 201-400 of SEQ:ID:NO: 1 of  
 EphB4 human receptor. The sequence includes the cysteine-rich domain and the first  
 fibronectin type III repeat and accordingly it was expected that several different  
 antigenic regions would be recognised. Six blocking peptides of 25 amino acids (overlap  
 by 5 amino acids, offset by 20 amino acids) were designed against specific amino acid  
 10 residues of EphB4 protein (SEQ ID NO.1) as indicated in Figure 11. The blocking  
 peptides have the following amino acid sequence:

|              |              |                           |
|--------------|--------------|---------------------------|
| Peptide 1    | SEQ ID NO:2: | TVNLTRFPETVPRELVVPVAGSCVV |
| Peptide 2    | SEQ ID NO:3: | GSCVVDAVPAPGPSPLYCREDGQW  |
| Peptide 3    | SEQ ID NO:4: | EDGQWAEQPVTCSCAPGFEEAEGN  |
| 15 Peptide 4 | SEQ ID NO:5: | AAEGNTKCRACAQGTKPLSGEGSC  |
| Peptide 5    | SEQ ID NO:6: | GEGSCQPCPANSHTIGSAVCQCR   |
| Peptide 6    | SEQ ID NO:7: | VCQCRVGYFRARTDPRGAPCTTPPS |

The peptides were tested for their ability to prevent cell death after pre-  
 incubation with the EphB4 polyclonal antibody (H-200 -Santa Cruz Biotechnology)  
 20 specifically directed to the extracellular domain amino residues 201 to 400 of EphB4  
 (SEQ ID NO:1). A cocktail of all the peptides was initially tested and successfully  
 prevented cell death as determined using trypan blue exclusion (Figure 12) and caspase-  
 3 activity assays (Figure 13). The peptides were then tested separately and partial rescue  
 was observed for Peptide 1 (SEQ ID NO:2) and Peptide 2 (SEQ ID NO:3) (see Figure 14).  
 25 Peptide 1 and Peptide 2 overlap by five amino acids residues (GSCVV designated SEQ  
 ID NO:13) indicating that this amino acid sequence corresponding to residues 221 to 225  
 of EphB4 (SEQ ID NO:1) is possibly the core of the reactive epitope.

Because the initial experiment with the cocktail of peptides effectively contained  
 twice the molar amount of the GSCVV (SEQ ID NO:13) sequence (ie residues 221 to 225  
 30 of EphB4 (SEQ ID NO:1)) a further blocking experiment in which twice the amount of  
 each of Peptide 1 (SEQ ID NO:2) and Peptide 2 (SEQ ID NO:3) was compared with the

initial amount of the peptides together. All treatments were successful in preventing tumour cell death caused by the EphB4 polyclonal antibody (H-200 from Santa Cruz) (see Figure 15).

Three new peptide (Peptides 7 to 9) of different lengths that span the GSCVV (SEQ ID nNO:13) core epitope sequence were made commercially based on specific amino acid residues of EphB4 protein (SEQ ID NO.1) as indicated in Figure 16. The blocking peptides have the following amino acid sequence:

|              |              |                  |
|--------------|--------------|------------------|
| Peptide 7    | SEQ ID NO:8: | AGSCVVDA         |
| Peptide 8    | SEQ ID NO:9  | VAGSCVVDAV       |
| 10 Peptide 9 | SEQ ID NO:10 | LVVPVAGSCVVDAVPA |

However, due to the high number of hydrophobic amino acids in peptides 8 and 9, these peptides were not soluble in any solution that could be applied to cells, thus preventing further testing. However, Peptide 7 (SEQ ID NO. 8) with an amino acid sequence corresponding to residues 220 to 227 of EphB4 (SEQ ID NO:1) was used in blocking experiments and was able to rescue cells from the cell death effect caused by the addition of the EphB4-antibody (H-200 from Santa Cruz) alone (see Figure 17).

All publications discussed above are incorporated herein in their entirety.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia or any other country before the priority date of each claim of this application.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

**References:**

1. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR) 2000. Cancer in Australia 1997. AIHW cat no. CAN10. Canberra: AIHW (Cancer Series no. 15).
- 5 2. Wang et al., 1998, Cell 93:741-753.
3. Dottori et al., 1998, PNAS 1998 95:13248-13253.
4. Easty et al., 1999, Int. J. Cancer 84:494-501.
5. Tickle and Altabef, 1999, Curr. Opin. Genet. Dev. 9:455-460.
6. Oates et al., 1999, Mech.Dev. 83:77-94.
- 10 7. O'Leary and Wilkinson, 1999, Curr. Opin. Neurobiol. 9:65-73.
8. Ward et al, 1989, Nature 341:544-546.
9. Van den Beuken T et al, 2001, J. Mol. Biol, 310, 591.
10. Bird et al, 1988, Science 242:423-426.
11. Huston et al., 1988 Proc. Natl. Acad. Sci. USA 85:5879-5883.
- 15 12. Holliger, P., et al 1993 Proc. Natl. Acad. Sci. USA 90:6444-6448.
13. Poljak, R.J., et al. 1994 Structure 2:1121-1123.
14. Kohler and Milstein (1975, Nature 256: 495-497.
15. Kozbor et al., 1983, Immunology Today 4: 72.
16. Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96.
- 20 17. Saraste and Pulkki, 2000, Cardiovascular Res. 45:528-53.
18. Tickle and Altabef (1999) Epithelial cell movements and interactions in limb, neural crest and vasculature. Curr. Opin. Genet. Dev. 9: 455 - 460
19. Mellitzer et al., 1999, Nature 400:77-81.
- 25 20. Bennett et al (1994) Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. J Biol Chem. 269:14211 - 14218.
21. Keydar et al (1979) Establishment and characterization of a cell line of human breast carcinoma origin. Eur. J Cancer 15:659-670.

## CLAIMS

1. A method for inhibiting cancerous growth of a cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located  
5 within residues 200 to 400 of EphB4 (SEQ ID NO: 1).
2. A method according to claim 1, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1).
3. A method according to claim 1 or 2, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID  
10 NO: 1).
4. A method according to any one of claims 1 to 3, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1).
5. A method for inhibiting cancerous growth of a cell, the method comprising  
15 contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID  
20 NO: 1).
6. A method according to claim 5, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 90% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO:  
25 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).
7. A method according to any one of claims 1 to 6, wherein the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).
8. A method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof,

wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1).

9. A method according to claim 8, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1).

5 10. A method according to claim 8 or 9, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1).

11. A method according to any one of claims 8 to 10, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1).

12. A method for inducing cell death of a cancer cell, the method comprising contacting the cell with at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).

13. A method according to claim 12, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 90% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).

14. A method according to any one of claims 8 to 13, wherein the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).

15. A method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 200 to 400 of EphB4 (SEQ ID NO: 1).


16. A method according to claim 15, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 201 to 245 of EphB4 (SEQ ID NO: 1).
17. A method according to claim 15 or 16, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 244 of EphB4 (SEQ ID NO: 1).
18. A method according to any one of claims 15 to 17, wherein the antibody or antigen-binding portion thereof binds to an epitope located within residues 220 to 230 of EphB4 (SEQ ID NO: 1).
19. A method for treating or preventing cancer in a subject, the method comprising administering to the subject an effective amount of at least one antibody or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 85% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).
20. A method according to claim 19, wherein the antibody or antigen-binding portion thereof binds to an epitope located in a sequence at least 90% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).
21. A method according to any one of claims 15 to 20, wherein the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).
22. A method of identifying an agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 200 to 400 of EphB4 (SEQ ID NO:1).
23. A method according to claim 22, wherein the method comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 201 to 245 of EphB4 (SEQ ID NO:1).

24. A method according to claim 22 or 23, wherein the method comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 220 to 244 of EphB4 (SEQ ID NO:1).
25. A method according to any one of claims 22 to 24, wherein the method  
5 comprising assessing the ability of the agent to bind to an EphB4 polypeptide within the region of residues 220 to 230 of EphB4 (SEQ ID NO: 1).
26. A method of identifying an agent which inhibits cancerous growth of a cell, the method comprising assessing the ability of the agent to bind to a polypeptide comprising a sequence at least 85% identical to residues selected from the group  
10 consisting of residues 200 to 400 of EphB4 (SEQ ID NO: 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).
27. A method according to claim 26, the method comprising assessing the ability of the agent to bind to a polypeptide comprising a sequence at least 90% identical to residues selected from the group consisting of residues 200 to 400 of EphB4 (SEQ ID NO:  
15 1), residues 201 to 245 of EphB4 (SEQ ID NO: 1), residues 220 to 244 of EphB4 (SEQ ID NO: 1) and residues 220 to 230 of EphB4 (SEQ ID NO: 1).
28. A method according to any one of claims 22 to 27, wherein the sequence has a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).
29. An agent which inhibits cancerous growth of a cell when identified by the  
20 method according to any one of claims 22 to 28.
30. A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1).
31. A purified EphB4 antibody according to claim 30, wherein the polypeptide has a sequence at least 90% identical to residues 201 to 245 of EphB4 (SEQ ID NO: 1).
- 25 32. A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1).
33. A purified EphB4 antibody according to claim 32, wherein the polypeptide has a sequence at least 90% identical to residues 220 to 244 of EphB4 (SEQ ID NO: 1).

34. A purified EphB4 antibody which binds to a polypeptide having a sequence at least 85% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1).
35. A purified EphB4 antibody according to claim 34, wherein the polypeptide has a sequence at least 90% identical to residues 220 to 230 of EphB4 (SEQ ID NO: 1).
- 5 36. A purified EphB4 antibody according to any one of claims 30 to 35, wherein the antibody binds to an epitope located in residues 200 to 400 of EphB4 (SEQ ID NO: 1).
37. A purified EphB4 antibody according to any one of claims 30 to 36, wherein the antibody binds to a polypeptide having a substitution of amino acid Asp (D) to Asn (N) at residue 226 of EphB4 (SEQ ID NO: 1).
- 10 38. A purified EphB4 antibody according to any one of claims 30 to 37, wherein the antibody is a monoclonal antibody.




Figure 1




2/20

Figure 2




3/20

Figure 3




4/20

Figure 4




5/20

Figure 5




6/20

Figure 6




7/20

Figure 7



8/20


Figure 8






9/20

Figure 9



10/20

Figure 10



11/20

**Figure 11**


201 TVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPSLYCREDGQWAEQPVGTGCS 254  
TVNLTRFPETVPRELVVPVAGSCVV (SEQ ID NO:2- Peptide 1)  
GSCVVDAVPAPGPSPSLYCREDGQW (SEQ ID NO:3- Peptide 2)  
EDGQWAEQPVGTGCS-

255 CAPGFEEAAEGNTKCRACAQGTFKPLSGEGSCQPCPANSHTIGSAVCQCRVGY 308  
CAPGFEEAEGN (SEQ ID NO:4- Peptide 3)  
AAEGNTKCRACAQGTFKPLSGEGSC (SEQ ID NO:5- Peptide 4)  
GEGSCQPCPANSHTIGSAVCQCR (SEQ ID NO: 6-  
Peptide 5)  
VCQCRVGY-

309 FRARTDPRGAPCTTPPSAPRSVVSRLNGSSLHLEWSAPLES GGREDLTALRCR 362  
FRARTDPRGAPCTTPPS (SEQ ID NO:7- Peptide 6)


12/20

Figure 12




13/20

Figure 13




14/20

Figure 14



15/20

Figure 15



16/20

**Figure 16**

201 TVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPLYCREDGQWAEQVGTGCS 254

TVNLTRFPETVPRELVVPVAGSCVV (SEQ ID NO:2- Peptide 1)

GSCVVDAVPAPGPSPLYCREDGQW (SEQ ID NO:3- Peptide 2)

AGSCVVDA (SEQ ID NO:8- Peptide 7)


VAGSCVVDAV (SEQ ID NO:9- Peptide 8)

LVVPVAGSCVVDAVPA (SEQ ID NO:10- Peptide 9)



17/20

Figure 17



18/20

**Figure 18**


SEQ ID NO:1

Homo Sapiens Ephrin type-B receptor 4 Precursor (EphB4)

|     |            |            |             |             |            |             |
|-----|------------|------------|-------------|-------------|------------|-------------|
| 1   | MELRVLLCWA | SLAAALÉETL | LNTKLETADL  | KWVTFPQVDG  | WEELSGLDE  | EQHSVRTYEV  |
| 61  | CDVQRAPGQA | HWLRTGWVPR | RGAVHVIYATL | RFTMLECLSL  | PRAGRSCKET | FTVFYYESDA  |
| 21  | DTATALTPAW | MENPYIKVDT | VAAEHLTRKR  | PGAEATGKVN  | VKTLRLGPLS | KAGFYLAFAQD |
| 181 | QGACMALLSL | HLFYKKCAQL | TVNLTRFPET  | VPRELVPVPA  | GSCVVDVPA  | PGSPSLYCR   |
| 241 | EDGQWAEQPV | TGCSCAPGFE | AAEGNTKCRA  | CAQGTFKPLS  | GEGSCQPCPA | NSHSNTIGSA  |
| 301 | VCQCRVGYFR | ARTDPRGAPC | TTPPSAPRSV  | VSRLNGSSLH  | LEWSAPLESG | GREDLTYALR  |
| 361 | CRECRPGGSC | APCGGDLTFD | PGPRDLVEPW  | VVVRGLRPDF  | TYTFEVTALN | GVSSLATGPV  |
| 421 | PFEPVNVTTD | REVPPAVSDI | RVTRSSPSSL  | SLAWAVPRAP  | SGAVLDYEVK | HEKGAEGPS   |
| 481 | SVRFLKTSN  | RAELRGLKRG | ASYLVQVRAR  | SEAGYGPFQ   | EHHSQTQLDE | SEGWREQLAL  |
| 541 | IAGTAVVGVV | LVLVVIVVAV | LCLRKQSNGR  | EAEYSDKHGQ  | YLIGHGTKVY | IDPFTYEDPN  |
| 601 | EAVREFAKEI | DVSYVKIEEV | IGAGEFGEVC  | RGRLLKAPGKK | ESCVAIKTLK | GGYTERQRRE  |
| 661 | FLSEASIMGQ | FEHPNIIRLE | GVVTNSMPVM  | ILTEFMENGA  | LDSFLRLNDG | QFTVIQLVGM  |
| 721 | LRGIASGMRY | LAEMSYVHRD | LAARNILVNS  | NLVCKVSDFG  | LSRFLEENSS | DPTYTSSLGG  |
| 781 | KIPRWTAPE  | AIAFRKFTSA | SDAWSYGIVM  | WEVMSFGERP  | YWDMSNQDVI | NAIEQDYRLP  |
| 841 | PPPDCTSLH  | QLMLDCWQKD | RNARPRFPQV  | VSALDKMIRN  | PASLKIVARE | GGASHPLLD   |
| 901 | QRQPHYSAFG | SVGEWLRAIK | MGRYEESFAA  | AGFGSFELVS  | QISAEDLLRI | GVTLAGHQKK  |
| 961 | ILASVQHMK  | QAKPGTPGGT | GGPAPQY     |             |            |             |

19/20

Figure 19



20/20


Figure 20

201 TVNLTRFPETVPRELVVPVAGSCVVDAVPAPGPSPLYCREDGGQWAEQPVTGCS 254


AGSCVVDAVPAPGPSPLYCREDGQ (Peptide 11, SEQ IDNO:12)

|

AGSCVVNAVAPGPSPLYCREDGQ (Peptide 10, SEQ ID NO:11)



Aspartate (D)



Asparagine (N)

1/10

## SEQUENCE LISTING

&lt;110&gt; The Queen Elizabeth Hospital

&lt;120&gt; Methods for regulating cancer

&lt;130&gt; 03 1348 7262

&lt;160&gt; 13

&lt;170&gt; PatentIn version 3.2

&lt;210&gt; 1

&lt;211&gt; 984

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

Met Glu Leu Arg Val Leu Leu Cys Trp Ala Ser Leu Ala Ala Ala Leu

1 5 10 15

Glu Glu Thr Leu Leu Asn Thr Lys Leu Glu Thr Ala Asp Leu Lys Trp

20 25 30

Val Thr Phe Pro Gln Val Asp Gly Trp Glu Glu Leu Ser Gly Leu Asp

35 40 45

Glu Glu Gln His Ser Val Arg Thr Tyr Glu Val Cys Asp Val Gln Arg

50 55 60

Ala Pro Gly Gln Ala His Trp Leu Arg Thr Gly Trp Val Pro Arg Arg

65 70 75 80

Gly Ala Val His Val Tyr Ala Thr Leu Arg Phe Thr Met Leu Glu Cys

85 90 95

Leu Ser Leu Pro Arg Ala Gly Arg Ser Cys Lys Glu Thr Phe Thr Val

100 105 110

SUBSTITUTE SHEET (RULE 26)

2/10

Phe Tyr Tyr Glu Ser Asp Ala Asp Thr Ala Thr Ala Leu Thr Pro Ala  
 115 120 125  
 Trp Met Glu Asn Pro Tyr Ile Lys Val Asp Thr Val Ala Ala Glu His  
 130 135 140  
 Leu Thr Arg Lys Arg Pro Gly Ala Glu Ala Thr Gly Lys Val Asn Val  
 145 150 155 160  
 Lys Thr Leu Arg Leu Gly Pro Leu Ser Lys Ala Gly Phe Tyr Leu Ala  
 165 170 175  
 Phe Gln Asp Gln Gly Ala Cys Met Ala Leu Leu Ser Leu His Leu Phe  
 180 185 190  
 Tyr Lys Lys Cys Ala Gln Leu Thr Val Asn Leu Thr Arg Phe Pro Glu  
 195 200 205  
 Thr Val Pro Arg Glu Leu Val Val Pro Val Ala Gly Ser Cys Val Val  
 210 215 220  
 Asp Ala Val Pro Ala Pro Gly Pro Ser Pro Ser Leu Tyr Cys Arg Glu  
 225 230 235 240  
 Asp Gly Gln Trp Ala Glu Gln Pro Val Thr Gly Cys Ser Cys Ala Pro  
 245 250 255  
 Gly Phe Glu Ala Ala Glu Gly Asn Thr Lys Cys Arg Ala Cys Ala Gln  
 260 265 270  
 Gly Thr Phe Lys Pro Leu Ser Gly Glu Gly Ser Cys Gln Pro Cys Pro  
 275 280 285  
 Ala Asn Ser His Ser Asn Thr Ile Gly Ser Ala Val Cys Gln Cys Arg  
 290 295 300  
 Val Gly Tyr Phe Arg Ala Arg Thr Asp Pro Arg Gly Ala Pro Cys Thr  
 305 310 315 320  
 Thr Pro Pro Ser Ala Pro Arg Ser Val Val Ser Arg Leu Asn Gly Ser  
 325 330 335

SUBSTITUTE SHEET (RULE 26)

3/10

Ser Leu His Leu Glu Trp Ser Ala Pro Leu Glu Ser Gly Gly Arg Glu  
 340 345 350  
 Asp Leu Thr Tyr Ala Leu Arg Cys Arg Glu Cys Arg Pro Gly Gly Ser  
 355 360 365  
 Cys Ala Pro Cys Gly Gly Asp Leu Thr Phe Asp Pro Gly Pro Arg Asp  
 370 375 380  
 Leu Val Glu Pro Trp Val Val Val Arg Gly Leu Arg Pro Asp Phe Thr  
 385 390 395 400  
 Tyr Thr Phe Glu Val Thr Ala Leu Asn Gly Val Ser Ser Leu Ala Thr  
 405 410 415  
 Gly Pro Val Pro Phe Glu Pro Val Asn Val Thr Thr Asp Arg Glu Val  
 420 425 430  
 Pro Pro Ala Val Ser Asp Ile Arg Val Thr Arg Ser Ser Pro Ser Ser  
 435 440 445  
 Leu Ser Leu Ala Trp Ala Val Pro Arg Ala Pro Ser Gly Ala Val Leu  
 450 455 460  
 Asp Tyr Glu Val Lys His Glu Lys Gly Ala Glu Gly Pro Ser Ser Val  
 465 470 475 480  
 Arg Phe Leu Lys Thr Ser Glu Asn Arg Ala Glu Leu Arg Gly Leu Lys  
 485 490 495  
 Arg Gly Ala Ser Tyr Leu Val Gln Val Arg Ala Arg Ser Glu Ala Gly  
 500 505 510  
 Tyr Gly Pro Phe Gly Gln Glu His His Ser Gln Thr Gln Leu Asp Glu  
 515 520 525  
 Ser Glu Gly Trp Arg Glu Gln Leu Ala Leu Ile Ala Gly Thr Ala Val  
 530 535 540  
 Val Gly Val Val Leu Val Leu Val Val Ile Val Val Ala Val Leu Cys  
 545 550 555 560

SUBSTITUTE SHEET (RULE 26)

4/10

Leu Arg Lys Gln Ser Asn Gly Arg Glu Ala Glu Tyr Ser Asp Lys His  
                   565                                  570                                  575  
 Gly Gln Tyr Leu Ile Gly His Gly Thr Lys Val Tyr Ile Asp Pro Phe  
                   580                                  585                                  590  
 Thr Tyr Glu Asp Pro Asn Glu Ala Val Arg Glu Phe Ala Lys Glu Ile  
                   595                                  600                                  605  
 Asp Val Ser Tyr Val Lys Ile Glu Glu Val Ile Gly Ala Gly Glu Phe  
                   610                                  615                                  620  
 Gly Glu Val Cys Arg Gly Arg Leu Lys Ala Pro Gly Lys Lys Glu Ser  
 625                                  630                                  635                                  640  
 Cys Val Ala Ile Lys Thr Leu Lys Gly Gly Tyr Thr Glu Arg Gln Arg  
                   645                                  650                                  655  
 Arg Glu Phe Leu Ser Glu Ala Ser Ile Met Gly Gln Phe Glu His Pro  
                   660                                  665                                  670  
 Asn Ile Ile Arg Leu Glu Gly Val Val Thr Asn Ser Met Pro Val Met  
                   675                                  680                                  685  
 Ile Leu Thr Glu Phe Met Glu Asn Gly Ala Leu Asp Ser Phe Leu Arg  
                   690                                  695                                  700  
 Leu Asn Asp Gly Gln Phe Thr Val Ile Gln Leu Val Gly Met Leu Arg  
 705                                  710                                  715                                  720  
 Gly Ile Ala Ser Gly Met Arg Tyr Leu Ala Glu Met Ser Tyr Val His  
                   725                                  730                                  735  
 Arg Asp Leu Ala Ala Arg Asn Ile Leu Val Asn Ser Asn Leu Val Cys  
                   740                                  745                                  750  
 Lys Val Ser Asp Phe Gly Leu Ser Arg Phe Leu Glu Glu Asn Ser Ser  
                   755                                  760                                  765  
 Asp Pro Thr Tyr Thr Ser Ser Leu Gly Gly Lys Ile Pro Ile Arg Trp  
                   770                                  775                                  780

SUBSTITUTE SHEET (RULE 26)



5/10

Thr Ala Pro Glu Ala Ile Ala Phe Arg Lys Phe Thr Ser Ala Ser Asp  
 785                      790                      795                      800  
 Ala Trp Ser Tyr Gly Ile Val Met Trp Glu Val Met Ser Phe Gly Glu  
                     805                      810                      815  
 Arg Pro Tyr Trp Asp Met Ser Asn Gln Asp Val Ile Asn Ala Ile Glu  
                     820                      825                      830  
 Gln Asp Tyr Arg Leu Pro Pro Pro Pro Asp Cys Pro Thr Ser Leu His  
                     835                      840                      845  
 Gln Leu Met Leu Asp Cys Trp Gln Lys Asp Arg Asn Ala Arg Pro Arg  
                     850                      855                      860  
 Phe Pro Gln Val Val Ser Ala Leu Asp Lys Met Ile Arg Asn Pro Ala  
 865                      870                      875                      880  
 Ser Leu Lys Ile Val Ala Arg Glu Gly Gly Ala Ser His Pro Leu Leu  
                     885                      890                      895  
 Asp Gln Arg Gln Pro His Tyr Ser Ala Phe Gly Ser Val Gly Glu Trp  
                     900                      905                      910  
 Leu Arg Ala Ile Lys Met Gly Arg Tyr Glu Glu Ser Phe Ala Ala Ala  
                     915                      920                      925  
 Gly Phe Gly Ser Phe Glu Leu Val Ser Gln Ile Ser Ala Glu Asp Leu  
                     930                      935                      940  
 Leu Arg Ile Gly Val Thr Leu Ala Gly His Gln Lys Lys Ile Leu Ala  
 945                      950                      955                      960  
 Ser Val Gln His Met Lys Ser Gln Ala Lys Pro Gly Thr Pro Gly Gly  
                     965                      970                      975  
 Thr Gly Gly Pro Ala Pro Gln Tyr  
                     980

SUBSTITUTE SHEET (RULE 26)

6/10

&lt;210&gt; 2

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Thr Val Asn Leu Thr Arg Phe Pro Glu Thr Val Pro Arg Glu Leu Val

1 5 10 15

Val Pro Val Ala Gly Ser Cys Val Val

20 25

&lt;210&gt; 3

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

Gly Ser Cys Val Val Asp Ala Val Pro Ala Pro Gly Pro Ser Pro Ser

1 5 10 15

Leu Tyr Cys Arg Glu Asp Gly Gln Trp

20 25

&lt;210&gt; 4

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

Glu Asp Gly Gln Trp Ala Glu Gln Pro Val Thr Gly Cys Ser Cys Ala

SUBSTITUTE SHEET (RULE 26)

7/10

1 5 10 15

Pro Gly Phe Glu Ala Ala Glu Gly Asn

20 25

&lt;210&gt; 5

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

Ala Ala Glu Gly Asn Thr Lys Cys Arg Ala Cys Ala Gln Gly Thr Phe

1 5 10 15

Lys Pro Leu Ser Gly Glu Gly Ser Cys

20 25

&lt;210&gt; 6

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

Gly Glu Gly Ser Cys Gln Pro Cys Pro Ala Asn Ser His Ser Asn Thr

1 5 10 15

Ile Gly Ser Ala Val Cys Gln Cys Arg

20 25

&lt;210&gt; 7

8/10

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

Val Cys Gln Cys Arg Val Gly Tyr Phe Arg Ala Arg Thr Asp Pro Arg

1

5

10

15

Gly Ala Pro Cys Thr Thr Pro Pro Ser

20

25

&lt;210&gt; 8

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

Ala Gly Ser Cys Val Val Asp Ala

1

5

&lt;210&gt; 9

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

Val Ala Gly Ser Cys Val Val Asp Ala Val

1

5

10

SUBSTITUTE SHEET (RULE 26)

9/10

&lt;210&gt; 10

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

Leu Val Val Pro Val Ala Gly Ser Cys Val Val Asp Ala Val Pro Ala

1

5

10

15

&lt;210&gt; 11

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

Ala Gly Ser Cys Val Val Asn Ala Val Pro Ala Pro Gly Pro Ser Pro

1

5

10

15

Ser Leu Tyr Cys Arg Glu Asp Gly Gln

20

25

&lt;210&gt; 12

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

Ala Gly Ser Cys Val Val Asp Ala Val Pro Ala Pro Gly Pro Ser Pro

1

5

10

15

SUBSTITUTE SHEET (RULE 26)

10/10

Ser Leu Tyr Cys Arg Glu Asp Gly Gln

20

25

&lt;210&gt; 13

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

Gly Ser Cys Val Val


1

5

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU03/01209

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>A. CLASSIFICATION OF SUBJECT MATTER</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Int. Cl. <sup>7</sup> : C07K 16/30; A61K 39/395; A61P 35/00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| According to International Patent Classification (IPC) or to both national classification and IPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| <b>B. FIELDS SEARCHED</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Minimum documentation searched (classification system followed by classification symbols)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Databases: Medline, Chemical Abstracts, WPIDS, Biosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Keywords: EphB4, HTK, antigen, epitope, antibody, cancer, tumour                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Category*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                               | Relevant to claim No.                                                                                                                                      |
| X, Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | BENNETT B. D. <i>et al.</i> , "Cloning and Characterization of HTK, a Novel Transmembrane Tyrosine Kinase of the EPH Subfamily", Journal of Biological Chemistry (1994), vol. 269, no. 19, pages 14211-14218<br>See whole document, especially page 14215, Figure 2 and Figure 5 | 1, 5, 6, 8, 12, 13, 15, 19, 20, 22, 26, 27                                                                                                                 |
| X, Y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | TAKAI N. <i>et al.</i> , "Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer", Oncology Reports (2001), vol. 8, no. 3, pages 567-573<br>See page 568, column 1                                   | 1, 5, 6, 8, 12, 13, 15, 19, 20, 22, 26, 27                                                                                                                 |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p> |                                                                                                                                                                                                                                                                                  |                                                                                                                                                            |
| Date of the actual completion of the international search<br>2 October 2003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                  | Date of mailing of the international search report<br>23 OCT 2003                                                                                          |
| Name and mailing address of the ISA/AU<br>AUSTRALIAN PATENT OFFICE<br>PO BOX 200, WODEN ACT 2606, AUSTRALIA<br>E-mail address: pct@ipaustalia.gov.au<br>Facsimile No. (02) 6285 3929                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                  | Authorized officer<br><br>ANDREW BRYCE<br>Telephone No : (02) 6283 2263 |

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/01209

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                    |                                            |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| Category*                                             | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                 | Relevant to claim No.                      |
| Y                                                     | STEPHENSON S.-A. <i>et al.</i> , "Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer", BMC Molecular Biology (2001), vol. 2, no. 1, article 15, pages 1-9<br>See whole document, especially page 3 and discussion on pages 5-7 | 1, 5, 6, 8, 12, 13, 15, 19, 20, 22, 26, 27 |
| A                                                     | HALL S. M. <i>et al.</i> , "Origin, Differentiation, and Maturation of Human Pulmonary Veins", American Journal of Respiratory Cell and Molecular Biology (2002), vol. 26, no. 3, pages 333-340<br>See Table I                                     |                                            |
| A                                                     | WO 02/26827 A1 (NOVARTIS AG), 4 April 2002<br>See Claim 1 and page 4, paragraph 5                                                                                                                                                                  |                                            |
| A                                                     | LIU W. <i>et al.</i> , "Coexpression of Ephrin-Bs and their Receptors in Colon Carcinoma", Cancer (2002), vol. 94, no. 4, pages 934-939<br>See page 936, column 1, paragraph 2                                                                     |                                            |



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/01209

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in<br>Search Report | Patent Family Member |
|-------------------------------------------|----------------------|
| WO 02/26827                               | AU 12292/02          |
| END OF ANNEX                              |                      |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**